Cargando…

Case report: Scleromyxedema associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins

Scleromyxedema is a rare idiopathic fibromucinous disorder characterized by a generalized papular and sclerodermoid cutaneous eruption. Patients often have praraproteinemia and extracutaneous, even lethal, manifestations. Yet the prognostic and therapeutic features of scleromyxedema are poorly docum...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shang-shang, Chen, Qin-yi, Xiang, Lei-hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880447/
https://www.ncbi.nlm.nih.gov/pubmed/36713453
http://dx.doi.org/10.3389/fimmu.2022.1099918
_version_ 1784878913433894912
author Wang, Shang-shang
Chen, Qin-yi
Xiang, Lei-hong
author_facet Wang, Shang-shang
Chen, Qin-yi
Xiang, Lei-hong
author_sort Wang, Shang-shang
collection PubMed
description Scleromyxedema is a rare idiopathic fibromucinous disorder characterized by a generalized papular and sclerodermoid cutaneous eruption. Patients often have praraproteinemia and extracutaneous, even lethal, manifestations. Yet the prognostic and therapeutic features of scleromyxedema are poorly documented. High-dose intravenous immunoglobulin (IVIG), used either alone or in conjunction with systemic steroids and/or thalidomide, has been suggested as a first-line treatment. We report the case of a 45-year-old woman diagnosed with scleromyxedema with paraproteinemia that initially did not respond to systemic steroids, retinoids, and thalidomide but greatly improvement in terms of systemic and cutaneous symptoms after treatment with IVIG.
format Online
Article
Text
id pubmed-9880447
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98804472023-01-28 Case report: Scleromyxedema associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins Wang, Shang-shang Chen, Qin-yi Xiang, Lei-hong Front Immunol Immunology Scleromyxedema is a rare idiopathic fibromucinous disorder characterized by a generalized papular and sclerodermoid cutaneous eruption. Patients often have praraproteinemia and extracutaneous, even lethal, manifestations. Yet the prognostic and therapeutic features of scleromyxedema are poorly documented. High-dose intravenous immunoglobulin (IVIG), used either alone or in conjunction with systemic steroids and/or thalidomide, has been suggested as a first-line treatment. We report the case of a 45-year-old woman diagnosed with scleromyxedema with paraproteinemia that initially did not respond to systemic steroids, retinoids, and thalidomide but greatly improvement in terms of systemic and cutaneous symptoms after treatment with IVIG. Frontiers Media S.A. 2023-01-13 /pmc/articles/PMC9880447/ /pubmed/36713453 http://dx.doi.org/10.3389/fimmu.2022.1099918 Text en Copyright © 2023 Wang, Chen and Xiang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Wang, Shang-shang
Chen, Qin-yi
Xiang, Lei-hong
Case report: Scleromyxedema associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins
title Case report: Scleromyxedema associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins
title_full Case report: Scleromyxedema associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins
title_fullStr Case report: Scleromyxedema associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins
title_full_unstemmed Case report: Scleromyxedema associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins
title_short Case report: Scleromyxedema associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins
title_sort case report: scleromyxedema associated with a monoclonal gammapathy: successful treatment with intravenous immunoglobulins
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880447/
https://www.ncbi.nlm.nih.gov/pubmed/36713453
http://dx.doi.org/10.3389/fimmu.2022.1099918
work_keys_str_mv AT wangshangshang casereportscleromyxedemaassociatedwithamonoclonalgammapathysuccessfultreatmentwithintravenousimmunoglobulins
AT chenqinyi casereportscleromyxedemaassociatedwithamonoclonalgammapathysuccessfultreatmentwithintravenousimmunoglobulins
AT xiangleihong casereportscleromyxedemaassociatedwithamonoclonalgammapathysuccessfultreatmentwithintravenousimmunoglobulins